Highest-materiality recent filing
Workforce reduction of ~50% approved June 14; estimated cash restructuring costs $5.7-6.4M, non-cash stock comp $4.7-5.0M.
enGene cuts workforce ~50%, CMO and CFO resign; Q2 loss widens to $30.2M
Workforce reduction of ~50% to streamline ops and preserve cash; restructuring costs est. $5.7-$6.4M cash plus $4.7-$5.0M non-cash stock comp.
enGene reports 54% CR at any time in Phase 2 LEGEND trial; 43% CR at 6 months
54% complete response (CR) at any time (67/124) and 43% CR at 6 months (52/121) in BCG-unresponsive NMIBC with CIS.
enGene Q1 net loss $29.8M; cash $312.5M; LEGEND data update at spring 2026 conference
Net loss $29.8M ($0.44/share) vs $24.6M ($0.48/share) year ago; operating expenses $31.2M.
enGene enters $100M at-the-market equity facility with Leerink Partners
New Sales Agreement with Leerink Partners for up to $100M in common shares via at-the-market offerings.
enGene expands debt facility with Hercules to $125M, $25M funded to refinance existing debt
Up to $125M debt facility from Hercules Capital; $25M funded at closing to refinance existing debt.
enGene expands loan facility to $125M; draws $25M initial tranche with Hercules Capital
Second Amendment increases term loan facility from $50M to up to $125M, with initial $25M advance to refinance prior debt.
FY2025 net loss $117.3M ($2.29/sh) vs $55.1M ($1.46/sh) in 2024; R&D expenses up $56.2M to $123.2M total OpEx.
enGene prices $130M public offering of common shares and pre-funded warrants
Pricing of 12,558,823 common shares at $8.50/share and pre-funded warrants for 2,735,295 shares at $8.4999 each.
Detalimogene 62% CR at 6 months; primary endpoint changed; BLA on track H2 2026
Post-protocol amendment patients achieved 62% CR at 6 months (n=37) and 63% at any time (n=62).
enGene appoints Dr. Hussein Sweiti as CMO; former J&J bladder cancer lead
Dr. Sweiti appointed Chief Medical Officer effective September 29, 2025.
enGene Q3 net loss $28.9M; hits LEGEND enrollment target, RMAT designation
Cash and marketable securities $224.9M; net loss $28.9M ($0.57/share) vs $14.1M ($0.32/share) YoY.
Target enrollment of 100 patients reached in Cohort 1 of Phase 2 LEGEND trial.
enGene appoints Astley-Sparke, Grossman, Heffernan to board; promotes three executives
Philip Astley-Sparke, William Grossman, Michael Heffernan appointed to Board effective July 8, 2025; Jasper Bos resigned.
enGene Q2 loss $25.8M ($0.51/shr); cash $251.5M; LEGEND study on track
Net loss $25.8M ($0.51/shr) vs $15.0M ($0.38) YoY; operating expenses $27.1M (up 57%).
enGene Q1 net loss $24.6M ($0.48/sh); cash $272.8M; LEGEND on track for BLA mid-2026
Net loss $24.6M ($0.48 per share) for Q1 ended Jan 31, 2025, vs $10.7M ($0.46) a year ago.
enGene enters $100M ATM equity sale agreement with Jefferies
Entered Open Market Sale Agreement with Jefferies for ATM offering of common shares up to $100M.
enGene reports FY2024 net loss $55.1M; cash $297.9M; LEGEND study on track for mid-2026 BLA
Net loss $55.1M ($1.46/sh) vs $104.7M in FY2023; operating expenses $62.3M up from $26.1M.
enGene raises $60M via private placement of 6.76M shares at $8.90/share
Gross proceeds ~$60M from sale of 6,758,311 common shares at $8.90/share; expected close Oct 29, 2024.
Detalimogene shows 71% CR rate in LEGEND pivotal cohort; well-tolerated in BCG-unresponsive NMIBC
71% complete response rate at any time (15/21 pts); 67% at 3 months; 47% at 6 months (8/17) in BCG-unresponsive NMIBC with Cis.
enGene appoints Ron Cooper as CEO, promotes Raj Pruthi to CMO; Hanson departs as planned
Ron Cooper appointed CEO and director effective July 22, 2024; Jason Hanson resigns but remains as strategic advisor.
enGene Q2 net loss $15.0M; plans EG-70 trial expansion for papillary-only NMIBC
Net loss of $15.0M ($0.38/share) vs $6.5M ($9.30/share) YoY; operating expenses $17.3M (up from $4.7M).
enGene Q1 net loss $10.7M; CEO to resign; $200M PIPE extends cash into 2027
Net loss $10.7M ($0.46/share) vs $8.6M ($13.29/share) YoY; operating expenses $10.8M vs $4.6M.
Sold 20M shares at $10.00 each (31% premium to Feb 13 close); gross proceeds $200M; expected close Feb 16.
enGene reports FY2023 net loss $104.7M; Phase 1 LEGEND study 68% CR rate, interim data mid-2024
FY2023 net loss $104.7M ($151.22/share) vs $29.0M ($44.30) in FY2022; operating expenses $26.0M.
enGene enters up to $50M term loan with Hercules Capital; draws $22.5M initially
Up to $50M term loan, initial $22.5M drawn, $8.6M refinances prior debt.
Ryan Daws appointed CFO and Head of Business Development, effective Nov 27, 2023; replaces Alexandre Grassin.
New enGene shares and warrants trade on Nasdaq under 'ENGN' and 'ENGNW' starting Nov 1, 2023.
On June 13, 2026, Dr. Hussein Sweiti notified the Company of his resignation from his position as Chief Medical Officer and Head of Research and Development of the Company, with his resignation to be effective as of June 14, 2026.
the Board appointed Kathleen Richton as Senior Vice President, Finance of the Company, with her appointment to become effective on or about July 16, 2026.
the Company announced that its Chief Financial Officer, Ryan Daws, will depart the Company effective July 15, 2026
On June 3, 2025, Dr. Raj S. Pruthi notified enGene Holdings Inc. (the “Company”) of his resignation from his position as Chief Medical Officer of the Company, with his resignation to be effective as of close of business on June 16, 2025.
Dr. Anthony Cheung’s title and role changed from Chief Technology Officer to Chief Scientific Officer
Mr. Ronald H.W. Cooper, assumed the additional title of President
Dr. Sullivan shall depart the Company effective October 31, 2024
Dr. Alexander Nichols’ title and role changed from President and Chief Operating Officer to Chief Strategy and Operations Officer
Mr. Hanson’s separation from the Company and resignation as a director became effective July 21, 2024, and his resignation is not the result of any disagreement with the Company.
Mr. Hanson will resign from his positions as Chief Executive Officer of the Company and as a member of the Company’s Board
On December 18, 2023, the Board of Directors (the “Board”) of enGene Holdings Inc. (the “Company”), increased its size from four members to five and, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Lota Zoth to the Board as a Class I Director of the Board, with a term expiring at the Company’s first annual general meeting following her appointment, or until her successor is duly elected and appointed.
On December 13, 2023, Ryan Daws, Chief Financial Officer of enGene Holdings Inc. (the “Company”), entered into an Executive Employment Agreement with enGene USA, Inc. (“enGene USA”), effective as of November 27, 2023 (the “Daws Employment Agreement”).
Max materiality 0.85 · Median 0.65 · Most common event other_material